Cantuzumab ravtansine

DB05594InvestigationalProtein Based Therapies

Investigated for use/treatment in gastric cancer.

Mechanism: Pharmacologically active on Mucin-1
Curator reviewed
Primary indication: Investigated for use/treatment in gastric cancer.Curator reviewed
Formula / weight: C₆₅₇₀H₁₀₁₃₀N₁₇₂₆O₂₀₁₈S₄₄(C₄₂H₅₉ClN₃O₁₁S₂)n
Code names: huC242-DM4 · IMGN-242

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cantuzumab ravtansine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.